Drug Trial Radar · NCT01700192
Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
Last checked: Nov 19, 2026Latest source record: Sep 15, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,482
Actual
Start
Jan 2013
Primary completion
Apr 2015
Study completion Apr 2015
Sponsor
- Lead sponsor
- ALK-Abelló A/SIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Oct 4, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of MK-8237 (SCH 900237) in the treatment of House Dust Mite (HDM)-Induced Allergic Rhinitis/Rhinoconjunctivitis (AR/ARC) in children and adults. The primary hypothesis of this study is that administration of MK-8237, compared to placebo, results in significant reduction in the average total combined rhinitis score (TCRS).
Conditions
- Rhinitis, Allergic, Perennial
- Rhinitis, Allergic, Nonseasonal
Interventions
MK-8237 tabletsBiological
MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d.
Placebo tabletsBiological
Placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d.
Rescue Medication: Self-Injectable EpinephrineDrug
Self-injectable epinephrine (preferred dose of 0.30 mg) administered intramuscularly as needed for rescue medication.
Rescue Medication: Loratadine tabletsDrug
Loratadine tablet 10 mg administered orally as needed for rescue medication.
Rescue Medication: Olopatadine ophthalmic dropsDrug
Olopatadine hydrochloride ophthalmic drops 0.1% administered as needed for rescue medication.
Rescue Medication: Mometasone furoate nasal sprayDrug
Mometasone furoate monohydrate nasal spray 50 mcg administered intranasally as needed for rescue medication.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Average Total Combined Rhinitis Score (TCRS) During Last 8 Weeks of TreatmentTime frame: Last 8 weeks of treatment (Weeks 44 to 52)
- Number of Participants Who Experience At Least One Adverse Event (AE)Time frame: Up to 54 weeks
- Number of Participants Who Discontinue Study Drug Due to an AETime frame: Up to 52 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.